Going on Trial: Serotonin drug; psilocybin phase 2; placebo response data
Peter Hess
The Transmitter 2023 DOI: 10.53053/etcr6498 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Psilocybin Serotonin |
| Keywords | Placebo response Pharmacology Drug trial Hallucinogen Clinical trial |
Abstract
Welcome to the April edition of Going on Trial, a monthly newsletter covering clinical trials and drug development for autism and related conditions.In this issue, we're talking about a serotonin agonist's path to trial for autism, debate around a trial of psilocybin for fragile X syndrome and an analysis of placebo responses in a clinical trial of the vasopressin blocker balovaptan.Feel free to email me at peter@spectrumnews.org with feedback on how this newsletter can better serve your needs as a researcher, and send me any tips you think readers should know about.In fact, this month's story on psilocybin